| | SARS-CoV-2-naive 个体 (n=7331) | SARS-CoV-2 暴露个体 (n=7339) | ä¿æŠ¤æ•ˆæžœ (95% CI)*
|
| | 人年累计éšè®¿â€
| å‘生事件的患者人数 | 人年累计éšè®¿â€
| å‘生事件的患者人数 |
|
任何严é‡ç¨‹åº¦çš„ rtPCR 确认的 COVID-19‡
| 1088·9 | 353 | 1192·5 | 65 | 83·2% (78·0 到 87·3) |
ä¸åº¦è‡³é‡åº¦ rtPCR 确诊 COVID-19 | 1088·9 | 73 | 1192·5 | 6 | 92·5% (82·9 到 97·3) |
ç» rtPCR ç¡®è®¤çš„ä¸¥é‡ COVID-19‡
| 1088·9 | 10 | 1192·5 | 0 | 100%(59·3 到 100) |
由于特定的识别å˜ä½“,对 rtPCR 确认的 COVID-19 çš„ä¿æŠ¤æ•ˆåŠ›ç»ˆç‚¹ |
| Alpha å˜ä½“ (B.1.1.7) | 1088·9 | 19 | 1192·5 | 0 | 100%(80·4 到 100) |
| Beta å˜ä½“(B.1.351ã€B.135.2ã€B.1.351.3) | 1088·9 | 23 | 1192·5 | 7 | 72·2% (33·1 到 89·9) |
| Delta å˜ä½“ (B.1.617.2) | 1088·9 | 72 | 1192·5 | 18 | 77·2%(61·3 至 87·2) |
| 伽玛å˜ä½“(P.1ï¼›P.1.1ï¼›P.1.2) | 1088·9 | 43 | 1192·5 | 3 | 93·6%(80·1 至 98·7) |
| Mu å˜ä½“ (B.1.621) | 1088·9 | 60 | 1192·5 | 5 | 92·4%(81·2 至 97·6) |
| Lambda å˜ä½“ (C.37) | 1088·9 | 7 | 1192·5 | 0 | 100%(36·7 到 100) |
| B.1.623 å˜ä½“ | 1088·9 | 8 | 1192·5 | 1 | 88·6%(14·9 至 99·7) |
| 其他 | 1088·9 | 121 | 1192·5 | 31 | 76·6% (65·1 到 84·8) |
| | 暴露于 SARS-CoV-2 çš„å‚与者 | SARS-CoV-2 幼稚å‚与者 |
| | SCB-2019+CpG 和明矾 | 安慰剂 | SCB-2019+CpG 和明矾 |
第 2 阶段安全装置 |
第一剂 |
| 任何请求的本地ä¸è‰¯äº‹ä»¶ | 263 åå‚与者ä¸çš„ 91 å (34·6% [28·9–40·7]) | 239 åå‚与者ä¸çš„ 18 å(7·5% [4·5–11·6]) | 484 åå‚与者ä¸çš„ 186 å (38·4% [34·1–42·9]) |
| 任何请求的系统性ä¸è‰¯äº‹ä»¶ | 263 åå‚与者ä¸çš„ 74 å (28·1% [22·8–34·0]) | 239 åå‚与者ä¸çš„ 71 å (29·7% [24·0–35·9]) | 484 åå‚与者ä¸çš„ 203 å (41·9% [37·5–46·5]) |
第二剂 |
| 任何请求的本地ä¸è‰¯äº‹ä»¶ | 243 åå‚与者ä¸çš„ 43 å (17·7% [24·8–31·6]) | 218 åå‚与者ä¸çš„ 19 å (8·7% [5·30–13·3]) | 406 åå‚与者ä¸çš„ 144 å (35·5% [30·8–40·3]) |
| 任何请求的系统性ä¸è‰¯äº‹ä»¶ | 243 åå‚与者ä¸çš„ 35 å (14·4% [10·2–19·5]) | 218 åå‚与者ä¸çš„ 38 å (17·4% [12·6–23·1]) | 406 åå‚与者ä¸çš„ 124 å (30·5% [26·1–35·3]) |
第 3 阶段安全装置 |
任何剂é‡åŽçš„ä¸è‰¯äº‹ä»¶ |
| ä¸è¯·è‡ªæ¥çš„ä¸è‰¯äº‹ä»¶ | 1039 个事件;7378 åå‚与者ä¸çš„ 731 å (9·9% [9·2–10·6]) | 1066 个事件;7379 åå‚与者ä¸çš„ 737 å (10·0% [9·3–10·7]) | 1676 个事件;7439 åå‚与者ä¸çš„ 1101 å (14·8% [14·0–15·7]) |
| 有关的 | 416 个事件;7378 åå‚与者ä¸çš„ 279 å(3·8% [3·4-4·2]) | 271 个事件;7379 åå‚与者ä¸çš„ 204 å (2·8% [2·4–3·2]) | 600 个事件;7439 åå‚与者ä¸çš„ 404 å (5·4% [4·9–6·0]) |
| 严é‡ä¸è‰¯äº‹ä»¶ | 19 events; 13 (<1% [0·1–0·3]) of 7378 participants | 19 events; 14 (<1% [0·1–0·3]) of 7379 participants | 28 events; 21 (<1% [0·2–0·4]) of 7439 participants |
Serious adverse event |
| Any | 30 events; 24 (<1% [0·2–0·5]) of 7378 participants | 26 events; 15 (<1% [0·1–0·3]) of 7379 participants | 31 events; 25 (<1% [0·2–0·5]) of 7439 participants |
| Related | 3 events; 3 (<1% [0·0–0·1]) of 7378 participants | 0 events; 0 (<1% [0·0–0·1]) of 7379 participants | 1 events; 1 (<1% [0·0–0·1]) of 7439 participants |
| Medically attended adverse event | 422 events; 320 (4·3% [3·9–4·8]) of 7378 participants | 485 events; 350 (4·7% [4·3–5·3]) of 7379 participants | 451 events; 331 (4·5% [4·0–5·0]) of 7439 participants |
| Adverse event of special interest | 22 events; 19 (<1% [0·2–0·4]) of 7378 participants | 35 events; 24 (<1% [0·2–0·5]) of 7379 participants | 260 个事件;7439 åå‚与者ä¸çš„ 164 å (2·2% [1·9–2·6]) |
| 导致æå‰é€€å‡ºçš„ä¸è‰¯äº‹ä»¶ | 2个事件;7378 åå‚与者ä¸çš„ 2 å (<1% [0·0–0·1]) | 7个事件;7379 åå‚与者ä¸çš„ 5 å (<1% [0·0–0·2]) | 3个事件;7439 åå‚与者ä¸çš„ 3 å(<1% [0·0–0·1]) |
| æ»äº¡ | 7个事件;7378 åå‚与者ä¸çš„ 2 å (<1% [0·0–0·1]) | 5个事件;7379 åå‚与者ä¸çš„ 3 å(<1% [0·0–0·1]) | 1个事件;7439 åå‚与者ä¸çš„ 1 å (<1% [0·0–0·1]) |